Chapter 1. Market Definition

                   
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Competitive Insights

Chapter 3. Market Dynamics
                    3.1. Drivers

                    3.2. Restraints

Chapter 4. Market Analysis
                        4.1. Porter’s Analysis
                            4.1.1. Supplier power
                            4.1.2. Buyer power
                            4.1.3. Threat of new entrant
                            4.1.4. Competitive rivalry

                        4.2. PESTEL Analysis

Chapter 5. Pricing Analysis

Chapter 6. Pipeline Analysis, By Phase

Chapter 7. Regulatory Framework
                       
Chapter 8. Market Segmentation : Market Estimates and Forecasts

8.1. Global Breast Cancer Drugs Market Estimates and Forecasts, by Cancer Type, Revenue (USD Million)

·       8.1.1. Hormone Receptor (ER+/HER2-): Market estimates and forecasts, 2018 to 2030 (USD Million)

·       8.1.2. HER2+: Market estimates and forecasts, 2018 to 2030 (USD Million)

·       8.1.3. Triple-Negative: Market estimates and forecasts, 2018 to 2030 (USD Million)

·         By Cancer Type (Hormone Receptor, HER2+, Triple-Negative) (Revenue, USD Million, 2018 - 2030)

·         By Therapy (Targeted therapy, Immunotherapy, Hormone Therapy, Chemotherapy) (Revenue, USD Million, 2018 - 2030)

1.      Genentech (ROCHE GROUP) – Herceptin, Perjeta, Phesgo, Kadcyla

2.      Pfizer Inc. – Ibrance, Tukysa

3.      Eli Lilly and Company - Verzenio

4.      Novartis – Kisqali, Piqray, Afinitor, Femara

5.      Merck & Co., Inc. – Keytruda

6.      AstraZeneca – Enhertu, Lynparza, Truqap, Faslodex, Arimidex

7.      DAIICHI SANKYO – Enhertu

8.      Gilead Sciences, Inc.– Trodelvy

9.      Puma Biotechnology, Inc.– Nerlynx

10.   MacroGenics, Inc.– Margenza

11.    Bristol-Myers Squibb Company - Abraxane